Showing 5771-5780 of 8080 results for "".
- Diclofenac, Silymarin Show Promise for Preventing Chemotherapy-Induced Hand-Foot Syndrome: Meta-analysishttps://practicaldermatology.com/news/diclofenac-silymarin-show-promise-for-preventing-chemotherapy-induced-hand-foot-syndrome-meta-analysis/2485939/Diclofenac and topical silymarin reduced the risk of grade 2 or higher chemotherapy-induced hand-foot syndrome (HFS), according to a new meta-analysis of randomized clinical trials evaluating pharmacologic preventive strategies.
- Phase 3: QTORIN™ Rapamycin Meets All Primary, Secondary Endpoints in Microcystic Lymphatic Malformationshttps://practicaldermatology.com/news/phase-3-qtorin-rapamycin-meets-all-primary-secondary-endpoints-in-microcystic-lymphatic-malformations/2485806/Palvella Therapeutics, Inc. announced positive topline results from the Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs), a rare, congenital vascular anomaly with no US Food and Drug Admin
- Analysis: Biologics Linked to Lower Cardiometabolic Risk in HShttps://practicaldermatology.com/news/analysis-biologics-linked-to-lower-cardiometabolic-risk-in-hs/2485805/Biologics were associated with a lower incidence of type 2 diabetes mellitus (T2DM) and cardiovascular events vs. no biologic use in a TriNetX cohort of 291,283 patients with hidradenitis suppurativa (HS), according to a new study in the Journal of Drugs in Dermatology. Investigat
- Remibrutinib Data at AAAAI Suggests Potential Expansion Beyond CSUhttps://practicaldermatology.com/news/remibrutinib-data-at-aaaai-highlight-expanded-potential-beyond-csu/2485784/New data on the selective Bruton’s tyrosine kinase inhibitor remibrutinib (Rhapsido) is slated for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, to be held February 27 to March 2 in Philadelphia.
- LIBERTY-CSU CUPID-C: Improved Itch in Spontaneous Chronic Urticaria with Dupliumabhttps://practicaldermatology.com/news/liberty-csu-cupid-c-improved-itch-in-spontaneous-chronic-urticaria-with-dupliumab/2485781/Dupilumab significantly reduced itch and hives severity in patients with chronic spontaneous urticaria (CSU) who remained symptomatic despite histamine 1–receptor antagonist (H1-AH) therapy, according to results from the phase 3 LIBERTY-CSU CUPID-C trial published
- Economic Analysis Shows Wide Range in Annual Sunscreen Expenseshttps://practicaldermatology.com/news/economic-analysis-shows-wide-range-in-annual-sunscreen-expenses/2485778/A new 2025 economic evaluation of annual sunscreen costs found wide variation depending on unit pricing and clothing coverage. Investigators conducted the analysis from July through August 2025, modeling the cost of sunscreen
- Commentary: Is the IMQ Mouse Model Hindering Psoriasis Research?https://practicaldermatology.com/news/commentary-is-the-imq-mouse-model-hindering-psoriasis-research/2485698/A perspective piece in the Journal of Investigative Dermatology takes a criticial look at the imiquimod (IMQ) mouse model, suggesting its unversality and commonality may be impeding translational progress in psoriasis resea
- Study Details Creation of First Patient Decision Aid for Adult ADhttps://practicaldermatology.com/news/study-details-creation-of-first-patient-decision-aid-for-adult-ad/2485671/A new paper details the development of a patient decision aid (PDA) designed to support shared decision-making for adults with moderate to severe atopic dermatitis (AD), unique in this instance for targeting previously addressed systemic treatment selection for ad
- Analysis: Agent Orange Exposure Linked to Acral Melanoma Risk in US Veteranshttps://practicaldermatology.com/news/analysis-agent-orange-exposure-linked-to-acral-melanoma-risk-in-us-veterans/2485639/Acral melanoma (AM), a rare melanoma subtype, showed risk factor patterns in a large Veterans Affairs (VA)–based analysis spanning more than two decades, according to new data. In this case-control study of US veterans from 20
- Upadacitinib Shows Rapid, Durable Skin Pain Relief in Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/upadacitinib-shows-rapid-durable-skin-pain-relief-in-moderate-to-severe-atopic-dermatitis/2485627/Poster data presented at Winter Clinical Hawaii indicated rapid and sustained reductions in skin pain among adults and adolescents with moderate-to-severe atopic dermatitis (AD) treated with upadacitinib. The analysis emphasized skin pain as a clinically meaningful